73.2 ð åèçïŒé«åž«åè / PGY OSCEïŒ
73.2.0.1 ð Cram Sheet
73.2.0.1.1 ð¥ é« yield 10
- Tissue confirmation å¿ é
- TNM staging + Stage 0-IV
- ECOG 0-5 / Karnofsky 100-0
- PS ⥠3 äžé© intensive chemo
- MDT æ¯ cancer care æšæº
- SPIKES for bad news
- Paraneoplastic: SIADH (SCLC) / PTHrP (squamous) / LEMS (SCLC) / Trousseau (pancreatic)
- Lymphoma â excisional biopsy
- Molecular markers: HER2/ER/PR/EGFR/ALK/PD-L1/MSI/BRAF/KRAS
- Cancer emergencies 7: SCC / SVCS / TLS / HyperCa / FN / å¿å tamponade / ICP
73.2.0.2 â é« yield
73.2.0.2.2 Paraneoplastic Syndromes
| 系統 | çå矀 | ççš® |
|---|---|---|
| Endocrine | SIADH | SCLC |
| Endocrine | Cushingâs (ectopic ACTH) | SCLC, carcinoid |
| Endocrine | Hypercalcemia (PTHrP) | Squamous (lung, H/N, breast) |
| Endocrine | Hypoglycemia (IGF-2) | HCC, sarcoma |
| Neuro | LEMS (anti-VGCC) | SCLC |
| Neuro | Cerebellar (anti-Yo) | Ovarian |
| Neuro | Limbic encephalitis (anti-Hu) | SCLC |
| Neuro | Anti-NMDA-R | Ovarian teratoma |
| Hemato | Trousseau | Pancreatic, lung, GI |
| Hemato | DIC | APL (M3) |
| Derma | AN (sudden) | Gastric |
| Derma | Dermatomyositis | Ovarian, lung, GI, breast |
73.2.0.2.3 Molecular Markers
| Marker | Cancer | Drug |
|---|---|---|
| HER2 | Breast, gastric | Trastuzumab |
| ER/PR | Breast | Tamoxifen, AI |
| EGFR | Lung adeno | Osimertinib, gefitinib |
| ALK | Lung adeno | Alectinib, crizotinib |
| BRAF V600E | Melanoma, CRC, hairy cell | Dabrafenib + trametinib |
| KRAS G12C | NSCLC, CRC | Sotorasib |
| MSI-H | CRC, endometrial | Pembrolizumab |
| PD-L1 | Multiple | Pembrolizumab, nivolumab |
73.2.0.3 ð¯ èªææª¢æž¬
- ECOG range? â 0-5
- PS ⥠3 chemo? â äžé© intensive
- Lymphoma biopsy? â Excisional
- SCLC paraneoplastic 3? â SIADH, LEMS, Cushingâs
- Trousseau syndrome? â Migratory thrombophlebitis, å€ pancreatic
- PTHrP cancers? â Squamous (lung, H/N, breast)
- SPIKES 6 å? â Setting/Perception/Invitation/Knowledge/Emotions/Strategy
- HER2 drug? â Trastuzumab
- EGFR L858R drug? â Osimertinib
- MSI-H drug? â Pembrolizumab
â ïž AI èçš¿ã